ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT05843643
- Locations
- 🇨🇱
Hospital Guillermo Grant Benavente de Concepción /ID# 254841, Concepción, Bio-Bio, Chile
🇨🇳Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 253045, Beijing, Beijing, China
🇺🇸AZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona, United States
An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
- Conditions
- Crohn's Disease
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1019
- Registration Number
- NCT05841537
- Locations
- 🇩🇪
Dres. Ende / Weisflog /ID# 262038, Erfurt, Germany
🇩🇪MVZ Dres. Al-Kadi & Partner /ID# 260996, Iserlohn, Germany
🇩🇪Dres. Breitschwerdt/Glas/Gurtler /ID# 257612, Leipzig, Germany
A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants
- Conditions
- Healthy Volunteer
- Interventions
- Drug: ABBV-903 Tablet Form 1Drug: ABBV-903 Tablet Form 2
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05836506
- Locations
- 🇺🇸
Acpru /Id# 254926, Grayslake, Illinois, United States
An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
- Conditions
- Migraine
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT05827887
- Locations
- 🇮🇱
Assuta Ashdod Medical Center /ID# 260020, Ashdod, HaDarom, Israel
🇮🇱Soroka University Medical Center /ID# 254551, Be'er Sheva, HaDarom, Israel
🇮🇱Edith Wolfson Medical Center /ID# 269740, Holon, HaMerkaz, Israel
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT05822752
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
🇮🇹IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
🇺🇸Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
- Conditions
- Open-angle GlaucomaOAG
- Interventions
- Device: XEN45 Glaucoma Treatment SystemProcedure: Trabeculectomy
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 130
- Registration Number
- NCT05821855
- Locations
- 🇨🇳
Peking University people's hospital /ID# 265493, Beijing, Beijing, China
🇨🇳Peking University Third Hospital /ID# 243994, Beijing, Beijing, China
🇨🇳Xiamen Eye Center of Xiamen University /ID# 244000, Xiamen, Fujian, China
A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants
- Conditions
- Facial Volume Deficit
- Interventions
- Device: HAC 22L
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 61
- Registration Number
- NCT05818709
- Locations
- 🇩🇪
Dermatologische Gemeinschaftspraxis Mahlow /ID# 243805, Blankenfelde-Mahlow, Brandenburg, Germany
🇪🇸Instituto Medico Miramar /ID# 251640, Málaga, Malaga, Spain
🇩🇪Hautok and Hautok-cosmetics /ID# 243800, Muenchen, Germany
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 480
- Registration Number
- NCT05814627
- Locations
- 🇺🇸
Ochsner Clinic Foundation /ID# 254059, New Orleans, Louisiana, United States
🇧🇬Diagnostic consultative center Focus-5 /ID# 252555, Sofiya, Bulgaria
🇺🇸Beth Israel Deaconess Medical Center - Rheumatology /ID# 255029, Boston, Massachusetts, United States
An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 300
- Registration Number
- NCT05791526
- Locations
- 🇯🇵
Kinshukai Infusion Clinic /ID# 253199, Osaka-shi, Osaka, Japan
🇯🇵National Hospital Organization Osaka National Hospital /ID# 257042, Osaka-shi, Osaka, Japan
🇯🇵Osaka Metropolitan University Hospital /ID# 258319, Osaka-shi, Osaka, Japan
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: NX-13 250mgDrug: NX-13 750mgDrug: NX-13 Placebo
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT05785715
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Belgium
🇮🇹Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele, Milan, Italy
🇮🇹Azienda Ospedaliera - Universitaria Sant' Andrea, Roma, Italy